SPDL1 and non-small cell lung carcinoma: Recent work by Honjo’s group has shown that elevated plasma levels of sPD-1, sPD-L1, and sCTLA-4 correlate with resistance to anti-PD-1 therapy in NSCLC patients (Hayashi et al, 2024).